A year af­ter cost cuts, Nanobi­otix has a deal with J&J to li­cense its lead ra­dioen­hancer prod­uct

Nanobi­otix and John­son & John­son have struck a li­cens­ing deal for the French biotech’s lead prod­uct, an ex­per­i­men­tal ther­a­py de­signed to boost the ef­fi­ca­cy of ra­di­a­tion treat­ment.

Un­der the agree­ment an­nounced ear­ly Mon­day morn­ing, J&J will li­cense Nanobi­otix’s lead prod­uct, NBTXR3, for which the com­pa­ny is con­duct­ing a late-stage study in head and neck can­cers. J&J will start up a Phase II pro­gram in ad­vanced lung can­cer, and the com­pa­nies may al­so look at oth­er us­es, ac­cord­ing to a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER